Microbiota and IPF: hidden and detected relationships

Area of Science:

• Microbiology
• Pulmonology
• Immunology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis, likely involving chronic inflammation and multifactorial causes.
• Risk factors for IPF include endogenous factors (e.g., gastroesophageal reflux) and environmental exposures (e.g., smoking, dusts, microbial agents).
• The lung microbiota (LM) is increasingly recognized for its potential role in airway injury and fibrotic processes.

Purpose of the Study:

• To review the literature on the role of bacteria, viruses, and fungi in IPF pathogenesis.
• To explore how microbial interactions and immune modulation by the LM contribute to lung dysfunction and IPF development.
• To highlight the potential of LM analysis for developing personalized therapies for IPF.

Main Methods:

• Literature review of studies investigating the lung microbiota, virome, and mycobiome in IPF.
• Analysis of mechanisms by which microbial agents may induce epithelial cell injury and chronic inflammation.
• Examination of the interplay between different microbiotas and host immune responses in IPF.

Main Results:

• Microbial agents, including bacteria, viruses, and fungi, may act as etiological agents or co-factors in IPF.
• Persistent immune responses to microbial stimuli can influence fibroblast activity, contributing to repetitive alveolar injury.
• The cross-talk between local microbiotas and immune modulation are implicated in IPF pathogenesis.

Conclusions:

• The lung microbiota plays a potential role in the development and progression of idiopathic pulmonary fibrosis.
• Understanding microbial interactions and their impact on immune responses is crucial for IPF research.
• Analysis of the lung microbiota presents a promising avenue for future personalized therapeutic strategies in IPF.